Login to Your Account



Cellectis-Cellartis Join Forces, Focus on Personalized Medicine

By Nuala Moran
BioWorld International Correspondent

Wednesday, November 9, 2011
LONDON – Cellectis SA has completed the acquisition of Europe's leading private stem cell company, the Swedish/British Cellartis AB, owner of 30 proprietary stem cell lines, in a cash and shares deal valued at €30 million (US$41.4million).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription